Related Experiment Video
Updated: Aug 18, 2026
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Is lipoprotein (a)-apheresis useful?
1Institute for Blood Purification, Homburg/Saar, Germany. rolf.bambauer-praxis-homburg@t-online.de
Insights
Low-density lipoprotein (LDL) apheresis effectively lowers lipoprotein (a) [Lp(a)], a risk factor for cardiovascular disease. Further research is needed to clarify the clinical benefits of lowering Lp(a) in patients with coronary heart disease.
Area of Science:
- Cardiology
- Lipidology
- Vascular Biology
Background:
- Epidemiological studies link cholesterol, particularly low-density lipoprotein (LDL), to coronary sclerosis and morbidity.
- Elevated LDL cholesterol is a primary driver of arteriosclerosis and coronary heart disease (CHD).
- Lipoprotein (a) [Lp(a)] is recognized as a risk factor for premature cardiovascular and cerebrovascular diseases.
Purpose of the Study:
- To evaluate the efficacy of LDL-apheresis in lowering Lp(a) levels.
- To investigate the potential clinical benefits of Lp(a) reduction in patients with CHD and elevated Lp(a).
- To address the ongoing debate regarding the necessity of lowering Lp(a) to arrest CHD progression.
Main Methods:
- LDL-apheresis as a therapeutic intervention.
- Analysis of Lp(a) levels before and after treatment.
- Assessment of endothelial function and coronary tone.
- Comparison of apheresis with statins versus drug therapy alone (proposed).
Main Results:
- LDL-apheresis can significantly reduce elevated Lp(a) levels.
- LDL-apheresis may improve endothelium regulation and coronary tone.
- The clinical benefit of Lp(a) lowering, especially in the context of low LDL, requires further clarification.
Conclusions:
- LDL-apheresis is an effective method for lowering Lp(a).
- Its role in improving clinical outcomes, particularly in specific patient groups, warrants further investigation.
- More randomized clinical studies are essential to resolve controversies surrounding Lp(a) lowering for CHD management.
Abstract:
Numerous epidemiological investigations have shown the importance of cholesterol, and in particular low density lipoprotein (LDL), and of the lipoproteins in the development of coronary sclerosis. A continuing relationship between cholesterol levels and coronary morbidity has been established. The LDL concentration in the blood is, in particular, to be made responsible for the development of arteriosclerosis and especially of coronary heart disease (CHD). Lipoprotein (a) [Lp(a)], as a risk factor for premature cardiovascular and cerebrovascular diseases, can be lowered by LDL-apheresis. Especially in isolated high levels of Lp(a) with CHD or polygenic hypercholesterolemia with elevated Lp(a) levels, LDL-apheresis can be indicated and can be useful to improve endothelium regulation and induce changes in coronary tone by an increase in endothelial derived relaxing factor. Lipoprotein (a) can be dramatically lowered by LDL-apheresis, but clinical improvement especially by low LDL is not still not clarified. Studies with weekly apheresis with statins versus drug therapy alone are necessary. To clarify the controversial discussions of whether lowering Lp(a) may be unnecessary or necessary to arrest progression of CHD, more clinical and randomized studies are needed. Lipoprotein (a) can be also lowered by current LDL-apheresis methods.
More Related Videos
11:13Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
Published on: May 9, 2019
10:39Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
Published on: November 28, 2016